Synthesis	O
and	O
characterization	O
of	O
acetylated	B:C0002732
amylose	I:C0002732
and	O
development	O
of	O
inclusion	O
complexes	O
with	O
rifampicin	O
.	O

Synthesis	O
and	O
characterization	O
of	O
acetylated	O
amylose	I:C0002732
and	O
development	O
of	O
inclusion	O
complexes	O
with	O
rifampicin	B:C0035608
.	O

Amylose	B:C0002732
(	O
Amylose	O
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion	O
complexes	O
with	O
suitable	O
agents	O
.	O

Amylose	O
(	O
Amylose	B:C0002732
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion	O
complexes	O
with	O
suitable	O
agents	O
.	O

Amylose	O
(	O
Amylose	O
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion	O
complexes	O
with	O
suitable	O
agents	B:C0450442
.	O

These	O
complexes	B:C1704241
are	O
considered	O
promising	O
biomaterial	O
carrier	O
since	O
the	O
guest	O
molecules	O
can	O
be	O
released	O
later	O
,	O
leading	O
to	O
many	O
applications	O
,	O
especially	O
in	O
the	O
pharmaceutical	O
industry	I:C0013185
.	O

These	O
complexes	O
are	O
considered	O
promising	O
biomaterial	B:C0005479
carrier	O
since	O
the	O
guest	O
molecules	O
can	O
be	O
released	O
later	O
,	O
leading	O
to	O
many	O
applications	O
,	O
especially	O
in	O
the	O
pharmaceutical	O
industry	I:C0013185
.	O

These	O
complexes	O
are	O
considered	O
promising	O
biomaterial	O
carrier	O
since	O
the	O
guest	O
molecules	O
can	O
be	O
released	O
later	O
,	O
leading	O
to	O
many	O
applications	O
,	O
especially	O
in	O
the	O
pharmaceutical	B:C0013185
industry	I:C0013185
.	O

Rifampicin	B:C0035608
(	O
Rifampicin	O
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	O
against	O
Mycobacterium	O
tuberculosis	I:C0026926
,	O
however	O
,	O
the	O
administration	O
of	O
Rifampicin	O
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side	O
-	O
effects	O
.	O

Rifampicin	O
(	O
Rifampicin	B:C0035608
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	O
against	O
Mycobacterium	O
tuberculosis	I:C0026926
,	O
however	O
,	O
the	O
administration	O
of	O
Rifampicin	O
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side	O
-	O
effects	O
.	O

Rifampicin	O
(	O
Rifampicin	O
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	B:C1254351
against	O
Mycobacterium	O
tuberculosis	I:C0026926
,	O
however	O
,	O
the	O
administration	O
of	O
Rifampicin	O
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side	O
-	O
effects	O
.	O

Rifampicin	O
(	O
Rifampicin	O
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	O
against	O
Mycobacterium	B:C0026926
tuberculosis	I:C0026926
,	O
however	O
,	O
the	O
administration	O
of	O
Rifampicin	O
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side	O
-	O
effects	O
.	O

Rifampicin	O
(	O
Rifampicin	O
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	O
against	O
Mycobacterium	O
tuberculosis	I:C0026926
,	O
however	O
,	O
the	O
administration	B:C1533734
of	O
Rifampicin	O
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side	O
-	O
effects	O
.	O

Rifampicin	O
(	O
Rifampicin	O
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	O
against	O
Mycobacterium	O
tuberculosis	I:C0026926
,	O
however	O
,	O
the	O
administration	O
of	O
Rifampicin	B:C0035608
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side	O
-	O
effects	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	B:C0002732
(	O
Amylose	O
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5	O
gL	O
(	O
-	O
1	O
)	O
)	O
acetylated	O
amylose	I:C0002732
(	O
AMA	O
)	O
in	O
water	O
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
Amylose	B:C0002732
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5	O
gL	O
(	O
-	O
1	O
)	O
)	O
acetylated	O
amylose	I:C0002732
(	O
AMA	O
)	O
in	O
water	O
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
Amylose	O
)	O
in	O
the	O
formation	O
of	O
complexes	B:C1704241
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5	O
gL	O
(	O
-	O
1	O
)	O
)	O
acetylated	O
amylose	I:C0002732
(	O
AMA	O
)	O
in	O
water	O
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
Amylose	O
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5	O
gL	O
(	O
-	O
1	O
)	O
)	O
acetylated	B:C0002732
amylose	I:C0002732
(	O
AMA	O
)	O
in	O
water	O
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
Amylose	O
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5	O
gL	O
(	O
-	O
1	O
)	O
)	O
acetylated	O
amylose	I:C0002732
(	O
AMA	B:C0002732
)	O
in	O
water	O
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
Amylose	O
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5	O
gL	O
(	O
-	O
1	O
)	O
)	O
acetylated	O
amylose	I:C0002732
(	O
AMA	O
)	O
in	O
water	B:C0043047
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	O
(	O
trace	O
solubility	O
)	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	O
(	O
Amylose	O
)	O
in	O
the	O
formation	O
of	O
complexes	O
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0.5	O
gL	O
(	O
-	O
1	O
)	O
)	O
acetylated	O
amylose	I:C0002732
(	O
AMA	O
)	O
in	O
water	O
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	B:C0002732
(	O
trace	O
solubility	O
)	O
.	O

The	O
resulting	O
acetylated	B:C0002732
amylose	I:C0002732
was	O
characterized	O
by	O
means	O
of	O
Fourier	O
Transform	I:C0206055
Infrared	I:C0206055
(	I:C0206055
FT	I:C0206055
-	I:C0206055
IR	I:C0206055
)	I:C0206055
spectroscopy	I:C0206055
and	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
(	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
)	O
.	O

The	O
resulting	O
acetylated	O
amylose	I:C0002732
was	O
characterized	O
by	O
means	O
of	O
Fourier	B:C0206055
Transform	I:C0206055
Infrared	I:C0206055
(	I:C0206055
FT	I:C0206055
-	I:C0206055
IR	I:C0206055
)	I:C0206055
spectroscopy	I:C0206055
and	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
(	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
)	O
.	O

The	O
resulting	O
acetylated	O
amylose	I:C0002732
was	O
characterized	O
by	O
means	O
of	O
Fourier	O
Transform	I:C0206055
Infrared	I:C0206055
(	I:C0206055
FT	I:C0206055
-	I:C0206055
IR	I:C0206055
)	I:C0206055
spectroscopy	I:C0206055
and	O
Scanning	B:C0026020
Electron	I:C0026020
Microscopy	I:C0026020
(	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
)	O
.	O

The	O
resulting	O
acetylated	O
amylose	I:C0002732
was	O
characterized	O
by	O
means	O
of	O
Fourier	O
Transform	I:C0206055
Infrared	I:C0206055
(	I:C0206055
FT	I:C0206055
-	I:C0206055
IR	I:C0206055
)	I:C0206055
spectroscopy	I:C0206055
and	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
(	O
Scanning	B:C0026020
Electron	I:C0026020
Microscopy	I:C0026020
)	O
.	O

Fourier	B:C0206055
Transform	I:C0206055

Infrared	I:C0206055
results	O
indicated	B:C1444656
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	I:C0205148
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Infrared	I:C0206055
results	O
indicated	O
that	O
the	O
acetylation	B:C0001038
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	I:C0205148
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Infrared	I:C0206055
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	B:C0017725
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	I:C0205148
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Infrared	I:C0206055
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	B:C0002732
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	I:C0205148
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Infrared	I:C0206055
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	B:C0026020
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	I:C0205148
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Infrared	I:C0206055
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	B:C0205148
surfaces	I:C0205148
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Infrared	I:C0206055
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	I:C0205148
of	O
amylose	B:C0002732
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	O
.	O

Infrared	I:C0206055
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	I:C0205148
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	B:C0205148
after	O
acetylation	O
.	O

Infrared	I:C0206055
results	O
indicated	O
that	O
the	O
acetylation	O
of	O
anhydroglucose	O
units	O
of	O
amylose	O
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
Scanning	O
Electron	I:C0026020
Microscopy	I:C0026020
results	O
suggested	O
that	O
the	O
smooth	O
surfaces	I:C0205148
of	O
amylose	O
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	O
after	O
acetylation	B:C0001038
.	O

Ultraviolet	O
absorption	O
spectroscopy	O
(	O
UV	O
-	O
vis	O
)	O
analysis	B:C0936012
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
Amylose	O
-	O
Rifampicin	O
)	O
and	O
acetylated	O
(	O
AMA	O
-	O
Rifampicin	O
)	O
amylose	O
inclusion	O
complexes	O
.	O

Ultraviolet	O
absorption	O
spectroscopy	O
(	O
UV	O
-	O
vis	O
)	O
analysis	O
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
Amylose	B:C0002732
-	O
Rifampicin	O
)	O
and	O
acetylated	O
(	O
AMA	O
-	O
Rifampicin	O
)	O
amylose	O
inclusion	O
complexes	O
.	O

Ultraviolet	O
absorption	O
spectroscopy	O
(	O
UV	O
-	O
vis	O
)	O
analysis	O
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
Amylose	O
-	O
Rifampicin	B:C0035608
)	O
and	O
acetylated	O
(	O
AMA	O
-	O
Rifampicin	O
)	O
amylose	O
inclusion	O
complexes	O
.	O

Ultraviolet	O
absorption	O
spectroscopy	O
(	O
UV	O
-	O
vis	O
)	O
analysis	O
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
Amylose	O
-	O
Rifampicin	O
)	O
and	O
acetylated	O
(	O
AMA	B:C0002732
-	O
Rifampicin	O
)	O
amylose	O
inclusion	O
complexes	O
.	O

Ultraviolet	O
absorption	O
spectroscopy	O
(	O
UV	O
-	O
vis	O
)	O
analysis	O
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
Amylose	O
-	O
Rifampicin	O
)	O
and	O
acetylated	O
(	O
AMA	O
-	O
Rifampicin	B:C0035608
)	O
amylose	O
inclusion	O
complexes	O
.	O

Ultraviolet	O
absorption	O
spectroscopy	O
(	O
UV	O
-	O
vis	O
)	O
analysis	O
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
Amylose	O
-	O
Rifampicin	O
)	O
and	O
acetylated	O
(	O
AMA	O
-	O
Rifampicin	O
)	O
amylose	B:C0002732
inclusion	O
complexes	O
.	O

Their	O
characterization	O
in	O
solution	O
was	O
performed	O
by	O
dynamic	B:C1882368
light	I:C1882368
scattering	I:C1882368
(	O
dynamic	O
light	I:C1882368
scattering	I:C1882368
)	O
and	O
zeta	O
potential	O
(	O
ZP	O
)	O
measurements	O
.	O

Their	O
characterization	O
in	O
solution	O
was	O
performed	O
by	O
dynamic	O
light	I:C1882368
scattering	I:C1882368
(	O
dynamic	B:C1882368
light	I:C1882368
scattering	I:C1882368
)	O
and	O
zeta	O
potential	O
(	O
ZP	O
)	O
measurements	O
.	O

The	O
average	B:C0456389
size	I:C0456389
of	O
inclusion	O
complexes	O
as	O
determined	O
by	O
dynamic	O
light	I:C1882368
scattering	I:C1882368
,	O
ranged	O
between	O
70	O
and	O
100nm	O
.	O

The	O
average	O
size	I:C0456389
of	O
inclusion	O
complexes	O
as	O
determined	O
by	O
dynamic	B:C1882368
light	I:C1882368
scattering	I:C1882368
,	O
ranged	O
between	O
70	O
and	O
100nm	O
.	O

Besides	O
,	O
ZP	O
analysis	B:C0936012
showed	O
that	O
both	O
complexes	O
are	O
more	O
stable	O
in	O
the	O
presence	O
of	O
Rifampicin	O
.	O

Besides	O
,	O
ZP	O
analysis	O
showed	O
that	O
both	O
complexes	B:C1704241
are	O
more	O
stable	O
in	O
the	O
presence	O
of	O
Rifampicin	O
.	O

Besides	O
,	O
ZP	O
analysis	O
showed	O
that	O
both	O
complexes	O
are	O
more	O
stable	O
in	O
the	O
presence	B:C0150312
of	O
Rifampicin	O
.	O

Besides	O
,	O
ZP	O
analysis	O
showed	O
that	O
both	O
complexes	O
are	O
more	O
stable	O
in	O
the	O
presence	O
of	O
Rifampicin	B:C0035608
.	O

This	O
study	O
may	O
lead	O
to	O
the	O
development	O
of	O
an	O
effective	O
method	O
for	O
the	O
preparation	O
of	O
amylose	B:C0002732
inclusion	O
complexes	O
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	O
application	O
in	O
drug	O
delivery	I:C0085104
systems	I:C0085104
.	O

This	O
study	O
may	O
lead	O
to	O
the	O
development	O
of	O
an	O
effective	O
method	O
for	O
the	O
preparation	O
of	O
amylose	O
inclusion	O
complexes	O
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	B:C1517331
application	O
in	O
drug	O
delivery	I:C0085104
systems	I:C0085104
.	O

This	O
study	O
may	O
lead	O
to	O
the	O
development	O
of	O
an	O
effective	O
method	O
for	O
the	O
preparation	O
of	O
amylose	O
inclusion	O
complexes	O
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	O
application	O
in	O
drug	B:C0085104
delivery	I:C0085104
systems	I:C0085104
.	O

